Scarica l'app Stockscreener
542.12
2.43%
-13.48
Dopo l'orario di chiusura:
536.98
-5.14
-0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$555.60
Aprire:
$562.71
Volume 24 ore:
270.55K
Relative Volume:
0.77
Capitalizzazione di mercato:
$12.04B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-21.58
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+5.28%
1M Prestazione:
+23.22%
6M Prestazione:
+85.18%
1 anno Prestazione:
+70.97%
Intervallo 1D:
$540.01
$571.16
Intervallo di 1 settimana:
$505.00
$577.90
Portata 52W:
$265.00
$577.90
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
542.12 | 12.62B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Madrigal Pharmaceuticals (NASDAQ: MDGL) grants 2,125 RSUs to hires under inducement plan - Stock Titan
Jefferies 25: The Cardiometabolic Revolution Is Going Global - Citeline News & Insights
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating - MarketScreener
What margin trends mean for Madrigal Pharmaceuticals Inc. stockChart Signals & Momentum Based Trading Ideas - newser.com
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target - GuruFocus
Oppenheimer raises Madrigal Pharmaceuticals stock price target on positive Rezdiffra data - Investing.com Canada
Will Madrigal Pharmaceuticals Inc. stock pay special dividendsJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Madrigal Pharmaceuticals Inc. (YDO1) stock in buy zone after pullbackPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
How Madrigal Pharmaceuticals Inc. (YDO1) stock reacts to Fed tighteningJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Why Madrigal Pharmaceuticals Inc. (YDO1) stock is listed among top recommendationsTrade Ideas & Real-Time Price Movement Reports - newser.com
Madrigal Pharmaceuticals stock price target raised by Truist on MASH potential - Investing.com South Africa
Can Madrigal Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating - MarketScreener
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Short Interest & Long-Term Safe Investment Plans - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth storyWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceMarket Growth Report & Fast Gain Stock Tips - newser.com
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones - Yahoo Finance
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis - Yahoo Finance
Will Madrigal Pharmaceuticals Inc. (YDO1) stock sustain dividend payoutsWall Street Watch & Low Risk High Reward Ideas - newser.com
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning - MyChesCo
Madrigal Pharmaceuticals stock hits all-time high at 545.0 USD By Investing.com - Investing.com UK
Madrigal Pharma (NASDAQ: MDGL) sets fireside chats at three investor conferences - Stock Titan
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Madrigal Pharmaceuticals (BIT:1MDGL) Price Target Increased by 11.64% to 485.78 - Nasdaq
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):